Syndax Pharmaceuticals (SNDX) Set to Announce Earnings on Tuesday

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) is scheduled to issue its quarterly earnings data after the market closes on Tuesday, November 5th. Analysts expect the company to announce earnings of ($1.13) per share for the quarter.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last released its earnings results on Thursday, August 1st. The company reported ($0.80) earnings per share for the quarter, topping analysts' consensus estimates of ($0.91) by $0.11. The business had revenue of $3.50 million during the quarter. The firm's revenue for the quarter was up 3499999990.0% on a year-over-year basis. During the same quarter last year, the firm posted ($0.64) EPS. On average, analysts expect Syndax Pharmaceuticals to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Syndax Pharmaceuticals Trading Down 0.7 %

Shares of NASDAQ SNDX traded down $0.14 during mid-day trading on Wednesday, reaching $18.94. The company had a trading volume of 269,049 shares, compared to its average volume of 1,049,945. Syndax Pharmaceuticals has a 52 week low of $12.95 and a 52 week high of $25.34. The business's 50-day moving average is $19.20 and its 200-day moving average is $20.38. The stock has a market cap of $1.61 billion, a price-to-earnings ratio of -5.87 and a beta of 0.91.

Analyst Ratings Changes

A number of brokerages have recently commented on SNDX. JPMorgan Chase & Co. reduced their target price on shares of Syndax Pharmaceuticals from $34.00 to $33.00 and set an "overweight" rating on the stock in a research report on Tuesday, August 6th. Stifel Nicolaus raised their price objective on Syndax Pharmaceuticals from $40.00 to $41.00 and gave the stock a "buy" rating in a report on Monday, October 14th. UBS Group assumed coverage on Syndax Pharmaceuticals in a report on Thursday, October 24th. They issued a "buy" rating and a $37.00 target price for the company. Citigroup raised their price target on Syndax Pharmaceuticals from $30.00 to $34.00 and gave the company a "buy" rating in a research note on Friday, August 16th. Finally, HC Wainwright upped their price objective on shares of Syndax Pharmaceuticals from $41.00 to $45.00 and gave the stock a "buy" rating in a research note on Thursday, August 15th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $35.90.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).